The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease
- PMID: 21403858
- PMCID: PMC3049335
- DOI: 10.4061/2011/314082
The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease
Abstract
Mitochondrial dysfunction is a prominent feature of various neurodegenerative diseases as strict regulation of integrated mitochondrial functions is essential for neuronal signaling, plasticity, and transmitter release. Many lines of evidence suggest that mitochondrial dysfunction plays a central role in the pathogenesis of Parkinson's disease (PD). Several PD-associated genes interface with mitochondrial dynamics regulating the structure and function of the mitochondrial network. Mitochondrial dysfunction can induce neuron death through a plethora of mechanisms. Both mitochondrial dysfunction and neuroinflammation, a common denominator of PD, lead to an increased production of reactive oxygen species, which are detrimental to neurons. The transcription factor nuclear factor E2-related factor 2 (Nrf2, NFE2L2) is an emerging target to counteract mitochondrial dysfunction and its consequences in PD. Nrf2 activates the antioxidant response element (ARE) pathway, including a battery of cytoprotective genes such as antioxidants and anti-inflammatory genes and several transcription factors involved in mitochondrial biogenesis. Here, the current knowledge about the role of mitochondrial dysfunction in PD, Nrf2/ARE stress-response mechanisms, and the evidence for specific links between this pathway and PD are summarized. The neuroprotection of nigral dopaminergic neurons by the activation of Nrf2 through several inducers in PD is also emphasized as a promising therapeutic approach.
Figures
Similar articles
-
Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016. J Neurosci. 2016. PMID: 27277809 Free PMC article.
-
Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's disease.Med Res Rev. 2021 Mar;41(2):785-802. doi: 10.1002/med.21714. Epub 2020 Jul 18. Med Res Rev. 2021. PMID: 32681666 Review.
-
Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds.Pharmacol Res. 2016 Jan;103:80-94. doi: 10.1016/j.phrs.2015.11.019. Epub 2015 Nov 25. Pharmacol Res. 2016. PMID: 26626189 Review.
-
Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson's Disease.Antioxidants (Basel). 2022 Sep 9;11(9):1780. doi: 10.3390/antiox11091780. Antioxidants (Basel). 2022. PMID: 36139853 Free PMC article. Review.
-
Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson's Disease.Front Pharmacol. 2021 Nov 23;12:757161. doi: 10.3389/fphar.2021.757161. eCollection 2021. Front Pharmacol. 2021. PMID: 34887759 Free PMC article. Review.
Cited by
-
Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson's Disease.Molecules. 2020 Aug 7;25(16):3602. doi: 10.3390/molecules25163602. Molecules. 2020. PMID: 32784741 Free PMC article.
-
Haptoglobin is required to prevent oxidative stress and muscle atrophy.PLoS One. 2014 Jun 24;9(6):e100745. doi: 10.1371/journal.pone.0100745. eCollection 2014. PLoS One. 2014. PMID: 24959824 Free PMC article.
-
Adenovirus-Mediated Over-Expression of Nrf2 Within Mesenchymal Stem Cells (MSCs) Protected Rats Against Acute Kidney Injury.Adv Pharm Bull. 2015 Jun;5(2):201-8. doi: 10.15171/apb.2015.028. Epub 2015 Jun 1. Adv Pharm Bull. 2015. PMID: 26236658 Free PMC article.
-
Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes.J Clin Invest. 2016 Jun 1;126(6):2356-66. doi: 10.1172/JCI84870. Epub 2016 May 16. J Clin Invest. 2016. PMID: 27183391 Free PMC article.
-
The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases.Mol Neurobiol. 2016 Mar;53(2):1195-1219. doi: 10.1007/s12035-015-9090-9. Epub 2015 Jan 20. Mol Neurobiol. 2016. PMID: 25598355 Review.
References
-
- Lees AJ, Hardy J, Revesz T. Parkinson’s disease. The Lancet. 2009;373(9680):2055–2066. - PubMed
-
- Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission. 2003;110(5):517–536. - PubMed
-
- Navarro A, Boveris A. Brain mitochondrial dysfunction and oxidative damage in Parkinson’s disease. Journal of Bioenergetics and Biomembranes. 2009;41(6):517–521. - PubMed
-
- Witte ME, Geurts JJG, de Vries HE, van der Valk P, van Horssen J. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion. 2010;10(5):411–418. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
